CA9 and renal carcinoma: Since the enzymatic activity is believed to contribute to CAIX ability to promote tumor growth/survival [22], [23] and a carbonic anhydrase inhibitor has been reported to suppress invasion of renal cancer cells in vitro [44], the newly discovered CA-inhibitory antibodies can be tested for their anti-RCC activity in vivo, which could provide a different mechanism for RCC immune therapy.